CD4 and tuberculosis: Since 2019, the WHO has recommended that AlereLAM should be used to assist in the diagnosis of active TB in outpatient settings for PLHIV with CD4 ≤ 100 cells/μL and in those with either ‘seriously ill’ criteria or signs and symptoms of TB.8 While sensitivity is low in outpatient settings, the WHO has motivated that making AlereLAM available to all qualifying PLHIV presenting for care at any level of the health system would be a step towards ensuring earlier TB diagnosis and reducing mortality in those at greatest risk.1